Knowledge Management System of Hefei Institute of Physical Science,CAS
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China | |
Zhang, Xiangyu1; Zeng, Liang1; Li, Yizhi1; Xu, Qinqin2; Yang, Haiyan1; Lizaso, Analyn3; Mao, Xinru3; Jin, Ren'an4; Zeng, Yu5; Li, Qinglin6; Wang, Jianbo7; Li, Yang8; Zhang, Yongchang1,9; Yang, Nong1,9 | |
2021-02-10 | |
发表期刊 | CANCER IMMUNOLOGY IMMUNOTHERAPY |
ISSN | 0340-7004 |
通讯作者 | Zhang, Yongchang(zhangyongchang@csu.edu.cn) ; Yang, Nong(yangnong0217@163.cn) |
摘要 | Background This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Patients and methods SCLC (n = 28) and NSCLC (n = 177) patients who received treatment at Hunan Cancer Hospital between June 1, 2019, and July 1, 2020, were retrospectively analyzed. Progression-free survival (PFS) and treatment responses were compared among patients who received combination therapy of anlotinib plus PD-1 inhibitor, or monotherapy of either chemotherapy or PD-1 inhibitor. Independent prognostic factors were identified by Cox regression analysis. Results Patients with relapsed SCLC who received anlotinib plus PD-1 inhibitor as a >= second-line therapy (n = 14) had a significantly longer PFS than those who received PD-1 inhibitor alone (n = 14, 5.0 vs. 3.0 months; P = 0.005). For patients with previously untreated wild-type NSCLC, the combination therapy in the first-line setting (n = 6) provided a marginally longer PFS than mono-chemotherapy (n = 6, 8.0 vs. 3.0 months; P = 0.075). For patients with relapsed NSCLC, the combination therapy in the >= second-line setting (n = 62) resulted in significantly higher objective response rate (19.3 vs. 5.0 vs. 2.4%; P = 0.013) and longer PFS (8.0 vs. 2.0 vs. 2.0 months; P <0.001) as compared to monotherapy of either chemotherapy (n = 41) or PD-1 inhibitor (n = 62). Anlotinib and PD-1 blockade combination therapy was an independent predictive factor of longer PFS (P <0.001). Conclusion The combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC. |
关键词 | Anlotinib Immunotherapy Programmed death 1 inhibitor Lung cancer |
DOI | 10.1007/s00262-021-02869-9 |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Natural Science Foundation of China[81760529] ; Natural Science Foundation of Hunan Province[2018RS3106] ; Natural Science Foundation of Hunan Province[2018SK50901] ; Natural Science Foundation of Hunan Province[kq1801102] ; Natural Science Foundation of Hunan Province[2019-TJ-N04] ; Natural Science Foundation of Hunan Province[2019JJ50357] ; Natural Science Foundation of Hunan Province[2019SK4010] ; Natural Science Foundation of Hunan Province[2020JJ5340] ; Natural Science Foundation of Hunan Province[2020JJ3025] |
项目资助者 | Natural Science Foundation of China ; Natural Science Foundation of Hunan Province |
WOS研究方向 | Oncology ; Immunology |
WOS类目 | Oncology ; Immunology |
WOS记录号 | WOS:000616738100001 |
出版者 | SPRINGER |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/119645 |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Zhang, Yongchang; Yang, Nong |
作者单位 | 1.Cent South Univ, Hunan Canc Hosp, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit,Affiliated Canc, Changsha 410013, Peoples R China 2.Qinghai Prov Peoples Hosp, Xining 810000, Peoples R China 3.Burning Rock Biotech, Guangzhou 510300, Peoples R China 4.Zhejiang Univ, Sir Run Run Shaw Hosp, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China 5.Tongji Univ, Tongji Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 7.Shandong Univ, Dept Radiotherapy, Qilu Hosp, Jinan, Shandong, Peoples R China 8.Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei, Peoples R China 9.Univ South China, Grad Sch, Hengyang 421001, Hunan, Peoples R China |
推荐引用方式 GB/T 7714 | Zhang, Xiangyu,Zeng, Liang,Li, Yizhi,et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY,2021. |
APA | Zhang, Xiangyu.,Zeng, Liang.,Li, Yizhi.,Xu, Qinqin.,Yang, Haiyan.,...&Yang, Nong.(2021).Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.CANCER IMMUNOLOGY IMMUNOTHERAPY. |
MLA | Zhang, Xiangyu,et al."Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China".CANCER IMMUNOLOGY IMMUNOTHERAPY (2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论